论文部分内容阅读
目的 评价微粒化非诺贝特治疗混合型高脂血症 (Ⅱb)的疗效及耐受性。方法 将 12 0例混合型高脂血症随机分 2组 :A组 ( 60例 )每晚服微粒化非诺贝特 2 0 0mg;B组 ( 60例 )早、晚餐后各服血脂康 0 6g。2 4周后评价调脂效果 ,随访 1a。结果 2组均显著降低总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇(LDL -C)、载脂蛋白B(ApoB)和高密度脂蛋白胆固醇 (HDL -C)、载脂蛋白A1(ApoA1) (P <0 .0 5～ 0 .0 1) ;组间比较 ,A组升高HDL -C及降低TG较B组显著 (P <0 .0 5 )。 1a总心脑血管事件A组较B组有减少趋势 ,但P >0 .0 5。结论 微粒化非诺贝特对混合型高脂血症降低TG ,TC及LDL -C和升高HDL -C效果显著 ,副反应轻微 ,耐受性好。
Objective To evaluate the efficacy and tolerability of micronized fenofibrate in the treatment of mixed hyperlipidemia (Ⅱb). Methods A total of 120 cases of mixed hyperlipidemia were randomly divided into two groups: Group A (60 cases) received 200 mg fenofibrate per night; Group B (60 cases) 6g. 2 4 weeks after the evaluation of lipid-lowering effect, follow-up 1a. Results The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB) and high density lipoprotein cholesterol (HDL- Lipoprotein A1 (ApoA1) (P <0.05-0.01). Compared between groups, HDL-C and TG in group A were significantly higher than those in group B (P <0.05). 1a total cardiovascular events in group A than in group B there is a trend of decrease, but P> 0. Conclusion Micronized fenofibrate is effective in lowering TG, TC, LDL-C and increasing HDL-C in mixed hyperlipidemia with mild side effects and good tolerability.